Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Swagerty

Physician Assistant Owosso, MI Physician Assistant

NPI 1932731775 CMS profile 11160536

802 W King St Ste G, Owosso, MI 48867

Open in the dashboard

General payments

$19,492

1,427 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Swagerty of Owosso, MI is reported in the CMS Open Payments database as having received $19,492 across 1,427 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,089 411
2024 General $4,563 298
2023 General $3,340 252
2022 General $3,009 270
2021 General $2,491 196

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Swagerty
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Swagerty were reported at $6,089. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Swagerty Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,491 $132 $37–$438 $132
2022 $3,009 $155 $48–$522 $149
2023 $3,340 $167 $52–$557 $160
2024 $4,563 $178 $55–$600 $164
2025 $6,089 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $2,497 171 payments
  2. AbbVie, Inc. $2,327 194 payments
  3. Teva Pharmaceuticals USA, Inc. $2,195 174 payments
  4. Alkermes, Inc. $1,960 109 payments
  5. ITI, Inc. $1,793 137 payments
  6. Neurocrine Biosciences, Inc. $1,383 111 payments
  7. Janssen Pharmaceuticals, Inc $1,226 88 payments
  8. Lundbeck LLC $1,106 73 payments
  9. Axsome Therapeutics, Inc. $916 48 payments
  10. Sunovion Pharmaceuticals Inc. $751 98 payments
  11. Other $3,340 224 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,267 1,424 payments
  2. Education $225 3 payments
Products named General payments · program years 2021–2025
  1. ARISTADA Cns $1,847 107 payments
  2. ARISTADA Cns $1,847 107 payments
  3. LYBALVI $1,766 96 payments
  4. VRAYLAR $1,707 148 payments
  5. REXULTI $1,562 107 payments
  6. ARISTADA Cns $1,388 78 payments
  7. ARISTADA Cns $1,388 78 payments
  8. INGREZZA $1,207 97 payments
  9. CAPLYTA $1,150 94 payments
  10. ABILIFY MAINTENA $1,039 74 payments
  11. Other $13,687 983 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$15,809

Medicare's payments for the services billed

Medicare patients

87

Average age 58

Services billed

286

64 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Depression 56%
Arthritis 38%
Diabetes 31%
COPD 24%
Chronic kidney disease 22%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$706 — —
VRAYLAR
$552 — —
CAPLYTA
$460 — —
Austedo XR
$389 — —
ARISTADA
$333 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

1,427 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record